Navigation Links
Dragon Announces R&D Achievement in Biotech Manufacturing Process
Date:10/31/2007

VANCOUVER, Oct. 31 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. (TSX: DDD; OTCBB: DRUG; BBSE: DRP) today announced that its biotech method for 7ACA production has been successfully implemented on a new production line. Management believes this achievement validates the Company's research and development efforts to improve its manufacturing technology. This technology would bring immediate benefits to production operations by increasing production efficiency and by eliminating the use of chemicals thus reducing our disposal costs and protecting the environment. Further, we believe that the overall adoption of the technology in our operations will reduce production costs which would enhance the Company's competitiveness in global market.

Environmental protection issues are always challenging to the chemical manufacturers. Investments in waste treatment can provide solutions to comply with discharging regulations, but result in relatively higher high costs. Our implementation of biotech technology can assist in reducing this environmental waste.

7ACA is a key product of the Company and the traditional chemical manufacturing process involves the use of expensive solvents, toxic and pollutant reactants such as methylene chloride, N,N-dimethylaniline and trimethylchlorosilicane, which lead to toxic wastes that are difficult to recycle and costly to be properly discharged. Moreover, it must be operated under severe temperature conditions (-40 degrees C to -60 degrees C) for complex chemical reactions, and thus result in high energy costs.

Under the biotech method, enzymes will be used to catalyze reactions, therefore eliminating the use of expensive solvents and toxic reagents, leading to a considerable reduction in the waste generation. In addition, the biotech process operates at moderate temperature which consumes less energy.

Dragon has been dedicated to this biotech project since mid 2006 and has gone through trials. Further, samples have been sent to customers with our customers giving us confirmative feedback as to quality. The first commercial production line has been put into operation in October 2007 with a capacity of 10 tons per month, thus Dragon's total annual capacity for 7ACA increases from 600 tons to 720 tons. The Company plans to adopt this technology for all its 7ACA production.

As encouraged by this achievement, Dragon, as it always does, views research and development as a vital driver of its business strategy and is actively engaged in other major R&D activities, such as cephalosporin C fermentation project. As fermentation technology is one of the key factors that affect the costs and quality of its products, Dragon has established long term collaborations with East China University of Science and Technology to improve fermentation yield. This project has been listed as a key project under China National High-tech R&D Program - one major task of which is to develop strategically important technologies for biological and pharmaceutical industries during China's 10th Five-year Plan period. Currently, project team members are already in the critical stage of raw materials substitution test, bacteria selection test and fermentation process optimization.

This press release contains forward looking statements, including but not limited to, that the Company will continue to be able to improve its technology and product quality. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statements. Readers should not place undue reliance on forward looking statements, which only reflect the views of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports filed with the Securities and Exchange Commission.

CONTACT: Dragon Pharmaceutical Inc., Maggie Deng, Telephone: (604) 669-8817 or North America Toll Free: 1-877-388-3784, Email: irdragon@dragonpharma.com, Website: http://www.dragonpharma.com


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chinese pharma-biotech dragon rears its head
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 Four US Biotech ... today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), ... Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... Trends, market observers are growing more bullish on the ... reforms to free cash held overseas for tax reason ...
(Date:2/26/2017)... ... February 26, 2017 , ... Rob Lowe is a well recognized ... series, called "Informed," focuses on issues that are important to the American public and ... issue, which has been a hot topic around the world for a few years. ...
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive ... 2014, FireflySci had the goal of bringing their powerful cuvette and spectrophotometer ... the path that FireflySci is going on as they add yet another mark on ...
Breaking Biology Technology:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
Breaking Biology News(10 mins):